dc.creator | Siokas V., Arseniou S., Aloizou A.-M., Tsouris Z., Liampas I., Sgantzos M., Liakos P., Bogdanos D.P., Hadjigeorgiou G.M., Dardiotis E. | en |
dc.date.accessioned | 2023-01-31T09:56:47Z | |
dc.date.available | 2023-01-31T09:56:47Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.neulet.2021.135709 | |
dc.identifier.issn | 03043940 | |
dc.identifier.uri | http://hdl.handle.net/11615/79028 | |
dc.description.abstract | Background: Alzheimer's (AD) and Parkinson's diseases (PD) share a few elements of their clinical, pathological and genetic backgrounds. The CD33 rs3865444 has emerged as a strong genetic locus associated with AD through genome-wide association study (GWAS). However, little is known for its role in PD. Objective: To assess the role of CD33 rs3865444 on PD risk. Methods: We genotyped 358 patients with PD and 358 healthy controls for theCD33 rs3865444. Odds ratios (ORs) with the respective 95% confidence intervals (CIs)], were calculated with the SNPStats software, assuming five genetic models (co-dominant, dominant, recessive, over-dominant and log-additive), with the G allele as the reference allele. Results: The CD33 rs3865444 was associated with decreased PD risk in the dominant [GG vs GT + TT; OR (95% CI) = 0.61 (0.45−0.82), p = 0.001], the over-dominant [GG + TT vs GT; OR (95% CI) = 0.65 (0.48−0.89), p = 0.0061], log-additive [OR (95% CI) = 0.67 (0.52−0.86), p = 0.0014], and co-dominant [with overall p = 0.0043, and OR (95% CI) = 0.62 (0.45−0.84) for the TG genotype compared to the GG], modes of inheritance. Conclusions: The CD33 rs3865444 is associated with decreased PD risk, and larger studies investigating the role of CD33 rs3865444 on PD are needed. © 2021 Elsevier B.V. | en |
dc.language.iso | en | en |
dc.source | Neuroscience Letters | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101370261&doi=10.1016%2fj.neulet.2021.135709&partnerID=40&md5=47f2bb69f48818044695fe8642b0ecee | |
dc.subject | CD33 antigen | en |
dc.subject | genomic DNA | en |
dc.subject | CD33 antigen | en |
dc.subject | CD33 protein, human | en |
dc.subject | aged | en |
dc.subject | allele | en |
dc.subject | Article | en |
dc.subject | biological model | en |
dc.subject | case control study | en |
dc.subject | clinical feature | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | gene locus | en |
dc.subject | genetic association | en |
dc.subject | genome-wide association study | en |
dc.subject | genotype | en |
dc.subject | human | en |
dc.subject | inheritance | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | molecular genetics | en |
dc.subject | Parkinson disease | en |
dc.subject | priority journal | en |
dc.subject | recessive gene | en |
dc.subject | risk factor | en |
dc.subject | single nucleotide polymorphism | en |
dc.subject | Asian continental ancestry group | en |
dc.subject | genetic predisposition | en |
dc.subject | genetics | en |
dc.subject | genotype | en |
dc.subject | Parkinson disease | en |
dc.subject | risk factor | en |
dc.subject | Asian Continental Ancestry Group | en |
dc.subject | Genetic Predisposition to Disease | en |
dc.subject | Genome-Wide Association Study | en |
dc.subject | Genotype | en |
dc.subject | Humans | en |
dc.subject | Parkinson Disease | en |
dc.subject | Polymorphism, Single Nucleotide | en |
dc.subject | Risk Factors | en |
dc.subject | Sialic Acid Binding Ig-like Lectin 3 | en |
dc.subject | Elsevier Ireland Ltd | en |
dc.title | CD33 rs3865444 as a risk factor for Parkinson's disease | en |
dc.type | journalArticle | en |